Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is gaining traction in a rare kidney disease market, with early uptake of its newly approved treatment signaling a meaningful growth inflection that could reshape the company’s revenue outlook over the next several years.Bank of America Securities (BofA) on Wednesday upgraded Apellis Pharmaceuticals, citing the company’s underappreciated C3G opportunity.Analyst Tazeen Ahmad says the current valuation underappreciates the commercial potential of Empaveli in new rare ...